VIP (vasoactive intestinal peptide) differentially regulated human T-cell subsets — suppressing effector T-cells while supporting regulatory T-cells — with implications for restoring immune balance in rheumatoid arthritis.
Key findingVIP differentially modulated human T-cell subsets: suppressed CD4+ effector T-cell proliferation/activation while supporting CD4+CD25+ regulatory T-ce
What the researchers found
VIP differentially modulated human T-cell subsets: suppressed CD4+ effector T-cell proliferation/activation while supporting CD4+CD25+ regulatory T-cell function and survival — directly applicable to restoring the effector/regulatory T-cell balance in rheumatoid arthritis.
Why it matters
Relevant for neuropeptides, inflammation, immune-function.
How the study worked
in-vitro study.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis.
Brain, behavior, and immunity, 22(3), 312-7
Citation
Gutiérrez-Cañas, Irene; Juarranz, Yasmina; Santiago, Begoña; Martínez, Carmen; Gomariz, Rosa P; Pablos, José Luis; Leceta, Javier. (2008). Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis.. Brain, behavior, and immunity, 22(3), 312-7.